MARKET

BMRN

BMRN

BioMarin Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

118.67
-0.98
-0.82%
After Hours: 118.67 0 0.00% 16:45 08/07 EDT
OPEN
119.84
PREV CLOSE
119.65
HIGH
120.75
LOW
117.81
VOLUME
754.35K
TURNOVER
--
52 WEEK HIGH
131.95
52 WEEK LOW
62.88
MARKET CAP
21.46B
P/E (TTM)
180.35
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BMRN stock price target is 133.91 with a high estimate of 172.00 and a low estimate of 108.00.

EPS

BMRN News

More
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
Is (BMRN) Outperforming Other Medical Stocks This Year?
Zacks · 1d ago
BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
Zacks · 3d ago
How Biomarin Beat Expectations in Q2
You won't find many people who would complain about BioMarin Pharmaceutical's (NASDAQ: BMRN) performance so far this year. Here are the highlights from BioMarin's Q2 update. The company announced a net loss in the second quarter of $29.2 million, or $0.16 pe
Motley Fool · 4d ago
Biomarin Pharmaceutical Inc (BMRN) Q2 2020 Earnings Call Transcript
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. includin
Motley Fool · 4d ago
BioMarin Pharmaceutical EPS misses by $0.04, beats on revenue, expects FY20 GAAP profit
BioMarin Pharmaceutical (NASDAQ:BMRN): Q2 GAAP EPS of -$0.16 misses by $0.04. Revenue of $429.5M (+10.8% Y/Y) beats by $12.1M. For the FY20, BioMarin conti
seekingalpha · 4d ago
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 100.00% and 2.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4d ago
Lion Biotechnologies Reaches 80-Plus Relative Strength Rating Benchmark
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
Investor's Business Daily · 4d ago
Biomarin Pharmaceutical Q2 EPS $(0.16) Misses $(0.11) Estimate, Sales $429.50M Beat $418.61M Estimate
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per
Benzinga · 4d ago

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About BMRN

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
More

Webull offers kinds of BioMarin Pharmaceutical Inc. stock information, including NASDAQ:BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.